VIR Biotechnology

biotech company

VIR Nasdaq SEC CIK 1706431
Follow VIR Biotechnology Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$96.3M +41% vs same quarter last year
EPS, diluted −$0.57 +51.3% vs same quarter last year
Operating cash flow −$106.1M +36.7% vs same quarter last year
Operating income −$104.7M +39.7% vs same quarter last year
Revenue by quarter
$12.4M
$3M
$1.2M
$240K
$64.1M
$238.9M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q2 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income10 fiscal years
  • Revenue
  • Net income
−$1B$0$1B$2BFY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$68.6M−$438M
FY24$74.2M−$522M
FY23$86.2M−$615.1M
FY22$1.6B$515.8M
FY21$1.1B$528.6M
FY20$76.4M−$298.7M
FY19$8.1M−$174.7M
FY18$10.7M−$115.9M
FY17$2.7M−$69.9M
FY16--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−4000%−3000%−2000%−1000%0%1000%FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY25100%−699.2%−638.9%
FY2498.9%−791.3%−703.4%
FY2396.8%−794%−713.8%
FY2290.9%51.6%31.9%
FY2194%38.4%48.3%
FY20100%−388.9%−391.1%
FY19100%−2199.7%−2159%
FY18-−1112.6%−1086.3%
FY17-−3009.5%−2579.5%
FY16---
Free cash flowOperating cash flow minus capital expenditure
−$1B$0$1B$2BFY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$396.6M
FY24−$453.7M
FY23−$800.4M
FY22$1.6B
FY21−$69.4M
FY20−$197.5M
FY19−$138.6M
FY18−$102.3M
FY17−$69.1M
FY16-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • VIR Biotechnology
  • Healthcare median
−3000%−2000%−1000%0%1000%FY17FY19FY21FY23FY25
Show the numbers
YearVIR BiotechnologyHealthcare median
FY25−638.9%−30.6%
FY24−703.4%−47%
FY23−713.8%−58%
FY2231.9%−80.4%
FY2148.3%−71.8%
FY20−391.1%−62.2%
FY19−2159%−46.2%
FY18−1086.3%−49.6%
FY17−2579.5%−45.9%
FY16-−36%